Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Nuvalent (Nasdaq: NUVL) announced that CEO James Porter, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:00 a.m. PT in San Francisco.
A live webcast of the presentation will be available in the company's Investors section at www.nuvalent.com and the webcast will be archived for 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – NUVL
On the day this news was published, NUVL gained 1.85%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Within Biotechnology peers, some names like AXSM (+3.72%) and LEGN (+2.19%) were up while others like RYTM (-0.32%) and ABVX (-2.38%) were down, indicating mixed sector action rather than a coordinated move tied to this conference update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Board appointment | Positive | +0.2% | Appointment of experienced oncology executive Ron Squarer to Board of Directors. |
| Nov 26 | Conference participation | Neutral | -0.7% | Management participation in Piper Sandler healthcare conference fireside chat webcast. |
| Nov 24 | Equity offering close | Negative | +0.3% | Closing of public offering and full exercise of underwriters’ option by selling holders. |
| Nov 19 | NDA acceptance | Positive | +0.8% | FDA acceptance of NDA for zidesamtinib in TKI pre-treated ROS1-positive NSCLC. |
| Nov 18 | Equity offering pricing | Negative | -3.5% | Pricing of large public offering of Class A common stock for ~$500M gross proceeds. |
Recent major events (NDA acceptance, equity offerings) produced modest but generally directionally consistent price reactions, while an offering close showed a slight divergence.
Over the past months, Nuvalent reported several milestones including an NDA acceptance for zidesamtinib in ROS1-positive NSCLC on Nov 19, 2025 and sizeable equity offerings announced and priced on Nov 18–24, 2025. A board addition on Dec 10, 2025 and prior conference participation on Dec 4, 2025 rounded out news flow. Today’s J.P. Morgan conference appearance continues a pattern of investor-facing events alongside advancing late-stage oncology programs and recent capital raises.
Market Pulse Summary
This announcement highlights Nuvalent’s participation in a major healthcare investor conference, offering management a platform to discuss its clinical programs and recent regulatory and financing milestones. Against a backdrop of NDA progress and completed equity offerings, investors may focus on any qualitative updates shared at the event. Key factors to watch include clarity around commercialization plans, development timelines for lead kinase inhibitors, and how the company frames its cash runway and strategic priorities.
Key Terms
kinase medical
AI-generated analysis. Not financial advice.
A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302647193.html
SOURCE Nuvalent, Inc.
FAQ
When will Nuvalent (NUVL) present at the J.P. Morgan Healthcare Conference?
Who will represent Nuvalent (NUVL) at the January 13, 2026 presentation?
How can investors watch the Nuvalent (NUVL) presentation on January 13, 2026?
Will the Nuvalent (NUVL) webcast be available after the J.P. Morgan presentation?
What topics will Nuvalent (NUVL) likely cover at the J.P. Morgan presentation on January 13, 2026?
Where is the 44th Annual J.P. Morgan Healthcare Conference presentation located for Nuvalent (NUVL)?
